The Nanjing Intermediate People’s Court rules in favour of an undertaking and its subsidiary in an abuse of dominance case against its suppliers of active pharmaceutical ingredient and awards the plaintif damages as compensation for anti-competitive conduct totally $10 million (Yangtze River)

On 18 March 2020 the Nanjing Intermediate People's Court (court) ruled in favor of Yangtze River Pharmaceutical Group and its subsidiary (Yangtze Pharma) in an abuse of dominance case against its suppliers of active pharmaceutical ingredients (API). The court awarded the plaintiffs a record amount of damages as compensation for the anti-competitive conduct: CN¥68.8 million (close to US$10 million). This judgment is expected to encourage more companies to come forward and bring antitrust lawsuits before the Chinese courts. Background Yangtze Pharma is a well-known pharmaceutical manufacturer based in Jiangsu Province, near Shanghai. In May 2019 Yangtze Pharma brought an antitrust lawsuit against Hefei Yigong Pharma and its subsidiary (Yigong), as well as Yigong's contract manufacturer.